Print Page  Close Window

Corporate Profile

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has enhanced potency and is the only once-weekly therapy intended for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California.

Presentation

DateTitle
05/11/17
Download Documentation Corporate Presentation May 2017
04/06/17
Download Documentation Analyst Day Presentation

Stock Information

CDTX (Common Stock)
PriceChange% ChangeVolume
$8.05 + 0.050.63%7,188
Previous CloseToday's OpenIntraday HighIntraday Low
$8.00$7.90$8.15$7.65
Exchange: NASDAQ (US Dollar)
07/21/17 10:10 a.m. ET
Refresh quote

 

Stock chart for: CDTX.O.  Currently trading at $8.05 with a 52 week high of $12.95 and a 52 week low of $5.65.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources